Technology area: Biotechnology & Pharmaceuticals
11 pending office actions • 10 art units • 10 examiners • 0 of 11 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Cancer Research Technology Limited has 11 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 10 distinct examiners and 10 distinct art units, showing a broad and distributed prosecution docket. Portfolio oversight should combine centralized tracking with separate review of the technical record for each assignment.
OUSPENSKI, ILIA I is the busiest examiner, with 2 pending matters. Those matters provide the clearest setting for checking recurring objections or response themes, while the remaining assignments require examiner- and art-unit-specific strategy.
Based on the USPTO statutory response window for each pending office action. 8 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 8 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (27%) |
| §103 only | 3 (27%) |
| Double-patenting + other | 2 (18%) |
| Multi-statute (no §101) | 2 (18%) |
| No statute on record | 1 (9%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OUSPENSKI, ILIA I | 2 | 77.3% | +20.6% |
| SMITH, EMILIE ALINE | 1 | 49.4% | +35.4% |
| BATES, KEENAN ALEXANDER | 1 | 44.9% | +79.8% |
| GRAFF, SHARON LEVINE | 1 | — | — |
| HASTINGS, ALISON AZAR | 1 | 62.5% | +42.1% |
| YU, DELPHINUS DOU YI | 1 | 33.3% | +0.0% |
| LIPPOLIS, ALEXANDRA ROSE | 1 | 47.2% | +63.6% |
| LAFAVE, ELIZABETH ROSE | 1 | 64.4% | +43.2% |
| SULLIVAN, STEPHANIE LAUREN | 1 | 57.1% | +38.1% |
| POHNERT, STEVEN C | 1 | 12.5% | +18.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18418855 | VECTOR FOR CANCER TREATMENT | BATES, KEENAN ALEXANDER | 92d overdue |
| 17911184 | Optimised Methods for Cleavage of Target Sequences | LIPPOLIS, ALEXANDRA ROSE | 34d |
| 18254324 | MEDIATORS OF GENE SILENCING | YU, DELPHINUS DOU YI | 56d |
| 18283540 | METHOD OF CHARACTERISING A CANCER | GRAFF, SHARON LEVINE | — |
| 17295338 | IMPROVEMENTS IN VARIANT DETECTION | POHNERT, STEVEN C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18418855 | VECTOR FOR CANCER TREATMENT | BATES, KEENAN ALEXANDER | 92d overdue |
| 17609691 | MEDIATORS OF GENE SILENCING | SULLIVAN, STEPHANIE LAUREN | 8d overdue |
| 17911184 | Optimised Methods for Cleavage of Target Sequences | LIPPOLIS, ALEXANDRA ROSE | 34d |
| 18421850 | COMPUTATIONAL METHODS FOR CLONAL NEOANTIGEN IDENTIFICATION | SMITH, EMILIE ALINE | 35d |
| 17781650 | SPATIAL BARCODING | LAFAVE, ELIZABETH ROSE | 40d |
| 17706028 | ANTI CD25 FC GAMMA RECEPTOR BISPECIFIC ANTIBODIES FOR TUMOR SPECIFIC CELL DEPLETION | OUSPENSKI, ILIA I | 57d |
| 17819234 | NOVEL ANTIBODIES AND COMBINED USE OF A TREG DEPLETING ANTIBODY AND AN IMMUNOSTIMULATORY ANTIBODY | OUSPENSKI, ILIA I | 77d |
| 18265063 | Aldehyde Dehydrogenase Inhibitors and Their Therapeutic Use | HASTINGS, ALISON AZAR | — |
| Art Unit | Apps |
|---|---|
| 1644 | 2 |
| 1686 | 1 |
| 1631 | 1 |
| 1687 | 1 |
| 1627 | 1 |
| 1636 | 1 |
| 1637 | 1 |
| 1684 | 1 |
| 1635 | 1 |
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18421850 | COMPUTATIONAL METHODS FOR CLONAL NEOANTIGEN IDENTIFICATION | SMITH, EMILIE ALINE | 1686 | §103 | Non-Final OA | 35d | Pending | Jan 24, 2024 |
| 18418855 | VECTOR FOR CANCER TREATMENT | BATES, KEENAN ALEXANDER | 1631 | §103§112 | Final Rejection | 92d overdue | Pending | Jan 22, 2024 |
| 18283540 | METHOD OF CHARACTERISING A CANCER | GRAFF, SHARON LEVINE | 1687 | §101§102§103§112 | Non-Final OA | — | Pending | Sep 22, 2023 |
| 18265063 | Aldehyde Dehydrogenase Inhibitors and Their Therapeutic Use | HASTINGS, ALISON AZAR | 1627 | §103 | Non-Final OA | — | Pending | Jun 02, 2023 |
| 18254324 | MEDIATORS OF GENE SILENCING | YU, DELPHINUS DOU YI | 1636 | §101§102§112Other | Non-Final OA | 56d | Pending | May 24, 2023 |
| 17911184 | Optimised Methods for Cleavage of Target Sequences | LIPPOLIS, ALEXANDRA ROSE | 1637 | §101§102 | Non-Final OA | 34d | Pending | Sep 13, 2022 |
| 17819234 | NOVEL ANTIBODIES AND COMBINED USE OF A TREG DEPLETING ANTIBODY AND AN IMMUNOSTIMULATORY ANTIBODY | OUSPENSKI, ILIA I | 1644 | §102§112DP | Final Rejection | 77d | Pending | Aug 11, 2022 |
| 17781650 | SPATIAL BARCODING | LAFAVE, ELIZABETH ROSE | 1684 | §103 | Non-Final OA | 40d | Pending | Jun 01, 2022 |
| 17706028 | ANTI CD25 FC GAMMA RECEPTOR BISPECIFIC ANTIBODIES FOR TUMOR SPECIFIC CELL DEPLETION | OUSPENSKI, ILIA I | 1644 | Other | Final Rejection | 57d | Pending | Mar 28, 2022 |
| 17609691 | MEDIATORS OF GENE SILENCING | SULLIVAN, STEPHANIE LAUREN | 1635 | §112DP | Final Rejection | 8d overdue | Pending | Nov 08, 2021 |
| 17295338 | IMPROVEMENTS IN VARIANT DETECTION | POHNERT, STEVEN C | 1683 | §103§112 | Final Rejection | — | Pending | May 19, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCancer Research Technology Limited has 11 pending office actions as of October 2026, spread across 10 art units and 10 examiners.
Ilia I Ouspenski has the most, with 2 of Cancer Research Technology Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
